Skip to Content

Vivos Inc RDGL

Morningstar Rating
$0.11 +0.01 (4.79%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RDGL is trading at a 37% discount.
Price
$0.10
Fair Value
$4.66
Uncertainty
Extreme
1-Star Price
$8.26
5-Star Price
$2.45
Economic Moat
Svb
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RDGL is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.10
Day Range
$0.100.12
52-Week Range
$0.040.12
Bid/Ask
$0.10 / $0.11
Market Cap
$42.65 Mil
Volume/Avg
2.6 Mil / 783,996

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1,589.43
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising highly insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Total Number of Employees
1

Valuation

Metric
RDGL
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
1,589.43
Price/Cash Flow
Price/Earnings
RDGL

Financial Strength

Metric
RDGL
Quick Ratio
6.53
Current Ratio
6.57
Interest Coverage
Quick Ratio
RDGL

Profitability

Metric
RDGL
Return on Assets (Normalized)
−167.89%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
−184.37%
Return on Assets
RDGL
See how this stock stacks up to its competitors with Morningstar Investor

Medical Devices Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
ABT
Abbott LaboratoriesBbsbdsgXwhhcgp$189.3 Bil
SYK
Stryker CorpFsyhvntmBjcss$130.1 Bil
MDT
Medtronic PLCZqhdrxdpRkbxhpv$109.3 Bil
BSX
Boston Scientific CorpJfrxnwpcQtcjmg$100.9 Bil
EW
Edwards Lifesciences CorpRrhmcgshDjgzzq$54.3 Bil
DXCM
DexCom IncGcjklqfdLqyph$54.1 Bil
ZBH
Zimmer Biomet Holdings IncFrjqcrgjJvgw$25.6 Bil
ALGN
Align Technology IncFwxmnvfQzcmml$24.7 Bil
PHG
Koninklijke Philips NV ADRXmytwkbbQpnwbw$18.8 Bil
PODD
Insulet CorpWbcnsggpdDqhjgjp$12.3 Bil

Sponsor Center